PLEKHF1

Across TCGA pan-cancer cohorts, PLEKHF1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PLEKHF1 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher PLEKHF1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PLEKHF1 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

GBM, UCEC, and CCRCC are the cancer types where PLEKHF1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.273	0.463	.001	20	view →
UCEC	OS	Tertile	II,III,IV	0.498	1.000	.014	8	view →
CCRCC	DFS	Quartile	All	0.835	1.000	.017	5	view →
LUAD	DFS	Tertile	All	0.799	0.455	.002	5	view →
PDAC	OS	Tertile	II,III,IV	0.736	0.905	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PLEKHF1–GBM (DFS)

Open the GBM breakdown →